Eric M. Robinson

发表

Associations between TERT promoter mutations and survival in superficial spreading and nodular melanomas in a large prospective patient cohort.

D. Polsky, I. Osman, Y. Shao, 2022, The Journal of investigative dermatology.

Impact of Comorbidities on Lung Cancer Screening Evaluation.

K. Sigel, J. Wisnivesky, M. Kale, 2022, Clinical lung cancer.

Association between Ki‐67 expression and clinical outcomes among patients with clinically node‐negative, thick primary melanoma who underwent nodal staging

D. Polsky, I. Osman, Y. Shao, 2018, Journal of surgical oncology.

The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies

Antonio Marchetti, Keith T Flaherty, Dennie T Frederick, 2015, Nature Genetics.

Identification of a Novel Pathogenic Germline KDR Variant in Melanoma

S. W. Han, T. Kirchhoff, I. Osman, 2015, Clinical Cancer Research.

Sensitivity of plasma BRAFmutant and NRASmutant cell‐free DNA assays to detect metastatic melanoma in patients with low RECIST scores and non‐RECIST disease progression

D. Polsky, D. Shelton, M. Furtado, 2016, Molecular oncology.

Outcomes in Melanoma Patients Treated with BRAF/MEK-Directed Therapy or Immune Checkpoint Inhibition Stratified by Clinical Trial versus Standard of Care

S. W. Han, D. Polsky, P. Ott, 2017, Oncology.

Impact of Socioeconomic Status and Ethnicity on Melanoma Presentation and Recurrence in Caucasian Patients

J. Stein, S. W. Han, D. Polsky, 2016, Oncology.

Outcomes in Melanoma Patients Treated with BRAF/MEK-Directed Therapy or Immune Checkpoint Inhibition Stratified by Clinical Trial versus Standard of Care

S. W. Han, D. Polsky, P. Ott, 2017, Oncology.